Alector, Inc. – NASDAQ:ALEC
Founder-led company
Alector stock price today
$2.14
+0.36
+20.22%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 12 hours
Alector stock price monthly change
-67.87%
month
Alector stock price quarterly change
-67.87%
quarter
Alector stock price yearly change
-77.61%
year
Alector key metrics
Market Cap | 176.96M |
Enterprise value | 404.42M |
P/E | -3.81 |
EV/Sales | 3.02 |
EV/EBITDA | -3.32 |
Price/Sales | 3.85 |
Price/Book | 2.40 |
PEG ratio | 0.01 |
EPS | -1.38 |
Revenue | 96.40M |
EBITDA | -136.29M |
Income | -120.61M |
Revenue Q/Q | -3.96% |
Revenue Y/Y | -23.29% |
Profit margin | -99.77% |
Oper. margin | -103.16% |
Gross margin | 0% |
EBIT margin | -103.16% |
EBITDA margin | -141.38% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAlector stock price history
Alector stock forecast
Alector financial statements
Average Price Target
$4
Potential upside: 86.91%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 56.21M | 1.37M | 2.45% |
|---|---|---|---|
| Sep 2023 | 9.10M | -44.47M | -488.25% |
| Dec 2023 | 15.19M | -41.43M | -272.77% |
| Mar 2024 | 15.89M | -36.07M | -227.01% |
| Jun 2023 | 708737000 | 512.43M | 72.3% |
|---|---|---|---|
| Sep 2023 | 672395000 | 509.84M | 75.82% |
| Dec 2023 | 621827000 | 487.66M | 78.43% |
| Mar 2024 | 635494000 | 456.58M | 71.85% |
| Jun 2023 | -43.00M | -21.81M | 881K |
|---|---|---|---|
| Sep 2023 | -46.54M | 16.96M | 0 |
| Dec 2023 | -46.07M | 18.07M | 590K |
| Mar 2024 | -61.34M | -11.76M | 71.10M |
Alector alternative data
| Aug 2023 | 273 |
|---|---|
| Sep 2023 | 239 |
| Oct 2023 | 239 |
| Nov 2023 | 239 |
| Dec 2023 | 246 |
| Jan 2024 | 246 |
| Feb 2024 | 246 |
| Mar 2024 | 244 |
| Apr 2024 | 244 |
| May 2024 | 244 |
| Jun 2024 | 244 |
| Jul 2024 | 244 |
Alector other data
58.89%
-3.22%
of ALEC is owned by hedge funds
145
-2
48.63M
-4.30M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Mar 2024 | 0 | 40723 |
| Jun 2024 | 0 | 53301 |
| Aug 2024 | 0 | 59750 |
| Sep 2024 | 0 | 56200 |
| Dec 2024 | 0 | 110053 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | GRASSO MARC officer: Chief Fi.. | Common Stock | 16,489 | $2.52 | $41,536 | ||
Sale | ROSENTHAL ARNON director, officer.. | Common Stock | 52,172 | $2.52 | $131,421 | ||
Sale | KENKARE-MITRA SARA officer: President and Head of .. | Common Stock | 26,500 | $2.52 | $66,754 | ||
Sale | ROMANO GARY officer: Chief Medical Officer | Common Stock | 14,892 | $2.52 | $37,513 | ||
Sale | GRASSO MARC officer: Chief Fi.. | Common Stock | 7,297 | $4.88 | $35,624 | ||
Sale | ROSENTHAL ARNON director, officer.. | Common Stock | 26,499 | $4.88 | $129,395 | ||
Sale | KENKARE-MITRA SARA officer: President and Head of .. | Common Stock | 13,926 | $4.88 | $67,987 | ||
Sale | ROMANO GARY officer: Chief Medical Officer | Common Stock | 8,478 | $4.88 | $41,390 | ||
Sale | SCHELLER RICHARD H director | Common Stock | 44,250 | $5.16 | $228,374 | ||
Sale | HAMMOND PAULA director | Common Stock | 10,500 | $5.07 | $53,183 |
| Quarter | Transcript |
|---|---|
| Q4 2023 27 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q2 2023 4 Aug 2023 | Q2 2023 Earnings Call Transcript |
Alector: Q4 2024 Data Release Could Provide Major Shift For Valuation
Alector: Good Data, Huge Cash, No Near Term Catalyst
Capitalizing On Inflammation's Role In Neurological Disease Part 2: INmune Bio
Alector: Trading At Cash Despite Late Stage CNS Pipeline
Alector: Advancement Of Third Alzheimer's Drug Brings About Huge Potential
MDA Breakout Stocks Week 40 - October 2022: Short-Term Picks To Give You An Edge
Alector, INmune Bio, Inflammation, And Alzheimer's Disease: One Piece Of The Puzzle
Alector: Potential In Neurology And Cancer Treatments
Anavex's Blarcamesine: Why It May Treat Alzheimer's Disease
-
What's the price of Alector stock today?
One share of Alector stock can currently be purchased for approximately $2.14.
-
When is Alector's next earnings date?
Unfortunately, Alector's (ALEC) next earnings date is currently unknown.
-
Does Alector pay dividends?
No, Alector does not pay dividends.
-
How much money does Alector make?
Alector has a market capitalization of 176.96M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 27.36% to 97.06M US dollars.
-
What is Alector's stock symbol?
Alector, Inc. is traded on the NASDAQ under the ticker symbol "ALEC".
-
What is Alector's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Alector?
Shares of Alector can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Alector's key executives?
Alector's management team includes the following people:
- Dr. Robert Paul M.D., Ph.D. Advisor(age: 57, pay: $568,500)
- Dr. Arnon Rosenthal Co-Founder, Chief Executive Officer & Director(age: 69, pay: $566,020)
- Dr. Robert S. King Chief Devel. Officer(age: 62, pay: $556,210)
- Mr. Calvin Yu Vice President of Fin.(age: 49, pay: $370,870)
- Dr. Tillman Ulf Gerngross Ph.D. Co-Founder & Chairman(age: 61, pay: $60,000)
-
Is Alector founder-led company?
Yes, Alector is a company led by its founders Dr. Arnon Rosenthal and Dr. Tillman Ulf Gerngross Ph.D..
-
How many employees does Alector have?
As Jul 2024, Alector employs 244 workers.
-
When Alector went public?
Alector, Inc. is publicly traded company for more then 6 years since IPO on 7 Feb 2019.
-
What is Alector's official website?
The official website for Alector is alector.com.
-
Where are Alector's headquarters?
Alector is headquartered at 131 Oyster Point Boulevard, South San Francisco, CA.
-
How can i contact Alector?
Alector's mailing address is 131 Oyster Point Boulevard, South San Francisco, CA and company can be reached via phone at +41 52315660.
-
What is Alector stock forecast & price target?
Based on 1 Wall Street analysts` predicted price targets for Alector in the last 12 months, the avarage price target is $4. The average price target represents a 86.91% change from the last price of $2.14.
Alector company profile:
Alector, Inc.
alector.comExchange:
NASDAQ
Full time employees:
241
Industry:
Biotechnology
Sector:
Healthcare
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
131 Oyster Point Boulevard
South San Francisco, CA 94080
South San Francisco, CA 94080
CIK: 0001653087
ISIN: US0144421072
CUSIP: 014442107
